相关实验视频
Updated: Jul 12, 2025

08:40
Chronic Salmonella Infection Induced Intestinal Fibrosis
Published on: September 22, 2019
7.2K
炎症性肠病的肠外表现与增加的生物循环有关
Madeline Alizadeh1, Osman Ali2, Raymond K Cross2
1Institute for Genome Sciences, University of Maryland School of Medicine, Baltimore, MD, USA.
Crohn's & colitis 360
|October 30, 2023
概括
患有炎症性肠病 (IBD) 和肠外表现 (EIM) 的患者通过更多的生物疗法循环治疗. 这表明EIM表明IBD更难治疗,需要进一步研究最佳生物策略.
科学领域:
- 胃肠病学 胃肠病学
- 免疫学 免疫学 免疫学
- 类风湿病学 类风湿病学
背景情况:
- 肠外表现 (EIM) 是炎症性肠病 (IBD) 的常见和衰弱的并发症.
- 生物疗法经常需要管理IBD与EIMs.
- 关于EIM是否影响患者使用的生物疗法数量的数据有限.
研究的目的:
- 研究IBD患者的EIM和生物疗法循环治疗之间的关联.
- 为了确定EIM患者是否需要比没有EIM的患者更多的生物治疗.
主要方法:
- 来自IBD注册表的潜在成年研究队列研究的456名患者的回顾性分析 (2016年12月 - 2021年1月).
- 纳入标准:有关EIM和生物用途的数据可用性.
- 对人口统计和临床特征的分析,包括年龄,疾病持续时间,性别,皮质类固醇使用和IBD类型.
主要成果:
- 118名患者有EIM,而338人没有.
- 患有EIM的患者显著更有可能接触到更多的生物药物,并通过更多的生物药物循环 (P=.006).
- 在克罗恩氏病 (CD) 患者中,EIM与大肠病中生物循环增加有关 (P=.050).
结论:
- 这是第一个评估IBD患者与EIMs生物循环的研究.
- EIM与增加的生物循环有关,特别是在患有大结肠病的CD中.
- EIM可能意味着更复杂的IBD,这证明了针对性生物疗法的研究和早期的先进治疗启动.
相关概念视频
Inflammatory Bowel Disease II: Crohn's Disease
263
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
263
Inflammatory Bowel Disease I: Ulcerative Colitis
192
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
192
Chronic Bowel Disorders: Introduction
459
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
459
Inflammatory Bowel Disease IV: Pharmacological Management
134
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
134
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
148
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
148
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
170
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
170

